GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (LTS:0HIY) » Definitions » Cyclically Adjusted Book per Share

Atara Biotherapeutics (LTS:0HIY) Cyclically Adjusted Book per Share : $155.85 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Atara Biotherapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Atara Biotherapeutics's adjusted book value per share for the three months ended in Dec. 2024 was $-16.604. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $155.85 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Atara Biotherapeutics's average Cyclically Adjusted Book Growth Rate was -1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-05-12), Atara Biotherapeutics's current stock price is $7.352. Atara Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $155.85. Atara Biotherapeutics's Cyclically Adjusted PB Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atara Biotherapeutics was 0.78. The lowest was 0.03. And the median was 0.11.


Atara Biotherapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Cyclically Adjusted Book per Share Chart

Atara Biotherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 165.72 183.35 155.85

Atara Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 183.35 164.57 168.36 170.11 155.85

Competitive Comparison of Atara Biotherapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Atara Biotherapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atara Biotherapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-16.604/133.1571*133.1571
=-16.604

Current CPI (Dec. 2024) = 133.1571.

Atara Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201503 173.738 99.621 232.224
201506 154.508 100.684 204.341
201509 294.570 100.392 390.711
201512 276.889 99.792 369.464
201603 265.822 100.470 352.304
201606 252.827 101.688 331.068
201609 234.144 101.861 306.083
201612 219.305 101.863 286.680
201703 200.287 102.862 259.275
201706 184.903 103.349 238.233
201709 168.265 104.136 215.159
201712 144.723 104.011 185.277
201803 250.105 105.290 316.302
201806 249.586 106.317 312.595
201809 220.731 106.507 275.963
201812 184.362 105.998 231.600
201903 153.312 107.251 190.345
201906 123.882 108.070 152.640
201909 147.086 108.329 180.796
201912 127.985 108.420 157.186
202003 107.219 108.902 131.100
202006 128.239 108.767 156.995
202009 114.579 109.815 138.934
202012 138.632 109.897 167.974
202103 118.655 111.754 141.379
202106 97.799 114.631 113.604
202109 87.734 115.734 100.942
202112 76.251 117.630 86.316
202203 60.042 121.301 65.911
202206 68.224 125.017 72.666
202209 49.305 125.227 52.427
202212 33.005 125.222 35.097
202303 16.820 127.348 17.587
202306 1.843 128.729 1.906
202309 -12.469 129.860 -12.786
202312 -23.305 129.419 -23.978
202403 -20.426 131.776 -20.640
202406 -22.608 132.554 -22.711
202409 -15.773 133.029 -15.788
202412 -16.604 133.157 -16.604

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Atara Biotherapeutics  (LTS:0HIY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Atara Biotherapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=7.352/155.85
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atara Biotherapeutics was 0.78. The lowest was 0.03. And the median was 0.11.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Atara Biotherapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Industry
Traded in Other Exchanges
Address
1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics Headlines

No Headlines